Cancer is a genetic disease that is currently classified not only by its tissue and cell type of origin but increasingly by its molecular composition. Increasingly, tumor classification and subtyping is being performed based upon the oncogene gains, tumor suppressor losses, and associated epigenetic and transcriptional features. However, cancers, including brain tumors, are also characterized by profound alterations in cellular metabolism. At present, even though signature mutations in known metabolic enzymes are recognized as being important, the metabolic landscape of tumors is not currently incorporated into tumor diagnostic categories. Here we describe a set of recent discoveries on metabolic reprogramming driven by mutations in the genes for the isocitrate dehydrogenase (IDH) and receptor tyrosine kinase (RTK) pathways, which are the most commonly observed aberrations in diffuse gliomas. We highlight the importance of oncometabolites to dynamically shift the epigenetic landscape in IDH-mutant gliomas, and c-Myc and mechanistic target of rapamycin (mTOR) complexes in RTK-mutated gliomas to adapt to the microenvironment through metabolic reprogramming. These signify the integration of the genetic mutations with metabolic reprogramming and epigenetic shifts in diffuse gliomas, shedding new light onto potential patient subsets, coupled with information to guide the development of new therapeutic opportunities against the deadly types of brain tumors.
INTRODUCTION -GENETICS MEETS METABOLISM IN GLIOMAS
Recent advances made through multidisciplinary molecular research on cancers using large-scale DNA methylation profiling and next-generation sequencing approaches have enabled the molecular stratification of diffuse gliomas by the combination of genetic aberrations rather than assessing the status of individual markers. [1] [2] [3] Importantly, the identification of distinct genetic profiles in each glioma has culminated in novel glioma classifications with diagnostic, prognostic and predictive molecular biomarkers (Fig. 1A) . 4 However, advancement to the next clinicopathological stage would require the elucidation of how these genetic abnormalities functionally drive glioma pathogenesis. Hanahan and Weinberg proposed that fundamental cancer hallmarks well explain the complexities of neoplastic disease during its evolution. 5 Importantly, metabolic reprogramming is an emerging core hallmark of cancer, and genetic aberrations, in combination with intrinsic and extrinsic molecular signaling, shift intracellular metabolism to support the demands of rapidly proliferating cancer cells, in order to facilitate energy production, biosynthesis of macromolecules, and maintenance of reductionoxidation (redox) reactions. 6, 7 The hallmark of this reprogramming is highlighted by aerobic glycolysis, termed "the Warburg effect", as well as other critical metabolic circuits including amino acid metabolism such as glutaminolysis, lipid and nucleotide synthesis, and reactive oxygen species (ROS) management. Furthermore, metabolic reprogramming could dynamically shift the epigenetic landscape, as exemplified by DNA and histone modifications, through the production of intermediary metabolites. 8 Recent studies have clearly demonstrated that cancer metabolism is activated by dynamic changes in signaling and transcriptional networks that is induced by activated oncogenes (e.g. epidermal growth factor receptor (EGFR), RAS, MYC) and deregulated tumor suppressor proteins (e.g. TP53, Rb) which are hallmark genetic aberrations for diffuse gliomas, including glioblastoma multiforme (GBM). 6, 7, 9 Additionally, mutations in intracellular metabolic enzymes are also involved in carcinogenesis, as is highlighted by the discovery of the gene for isocitrate dehydrogenase 1 (IDH1), or less commonly IDH2, gene mutations that are detected in more than 70% (Fig. 1B) . 10, 11 Therefore, unveiling the molecular mechanisms by which mutations in the gene for receptor tyrosine kinase (RTK) signaling system and IDH promote metabolic reprogramming in gliomas should shed new light on the contribution of genetic aberrations to glioma pathogenesis. Here we review a set of recent discoveries of cancer metabolism involving IDH-mutated LGGs and GBMs with wild-type IDH, primarily driven by mutations in RTK pathways. We also highlight the link between metabolic reprogramming and epigenetic changes downstream of cancer-causing mutations, potentially providing new therapeutic opportunities for these deadly brain tumors.
METABOLIC REPROGRAMMING IN DIFFUSE GLIOMAS

IDH mutations and oncometabolites in gliomas
The mutations in IDH1 and IDH2 that were reported in 2009 are considered to occur early in the gliomagenesis of (B) Immunohistochemistry for IDH1 (R132H) and ATRX is useful for the molecular classification of diffuse gliomas in adults. The presence of IDH mutation significantly affects the status of methylation phenotypes in gliomas. 1p/19q-codeletion and EGFR amplification can be detected by FISH: green, probes for centromere regions; red, probes for targeted regions. Arrow, palisading necrosis; arrowhead, microvasucular proliferation. ATRX, alpha thalassemia/mental retardation syndrome X-linked; CFO, classic for oligodendroglioma; codel, codeletion; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; G-CIMP, glioma with a CpG island methylator phenotype; IDH, isocitrate dehydrogenase; IDH1, isocitrate dehydrogenase 1; mt, mutant; RTK, receptor tyrosine kinase; TERT, telomerase reverse transcriptase; wt, wild-type. the vast majority of LGGs (grades II and III) and secondary GBMs (GBM, IDH-mutant). 10, 11 The IDH enzymes are involved in the oxidative carboxylation of isocitrate to α-ketoglutarate (α-KG) in the cytosol and mitochondria, and promote the reduction of nicotinamide adenine dinucleotide phosphate (NADP + ) to NADPH. Of note, mutant IDH is relevant to glioma pathogenesis through its association with metabolic reprogramming (Fig. 2) . Mutant IDH is known to gain a neomorphic activity that reductively converts α-KG to D(R)-2-hydroxyglutarate (D-2-HG) by consuming reductive equivalents NADPH required for the reduction of glutathione disulfide to GSH, thereby causing increased oxidative stress that promotes tumorigenesis. 12 The intermediary metabolite 2-HG in turn inhibits α-KGdependent dioxygenases in glioma, 13 leading to the intriguing idea that D-2-HG acts as an "oncometabolite".
Others reported that increased production of 2-HG stimulates the activity of hypoxia-inducible factor (HIF) and enhanced proliferation of human astrocytes. 14 24 Further, tricarboxylic acid (TCA) cycle anaplerosis is maintained primarily by glutamine, and hypoxic cells are able to maintain cell proliferation through wildtype IDH-dependent reductive carboxylation of glutamine-derived α-KG. 25, 26 Interestingly, the increased glutamine-derived α-KG in hypoxia is also associated with a concomitant increase of 2-HG produced by wild-type IDH, and the reductive carboxylation of glutamine is part of the metabolic reprogramming associated with HIF. 27 Therefore, hypoxia could be central to promote metabolic reprogramming in IDH-wild-type gliomas, which could be targeted with a novel therapeutic strategy.
RTK pathway aberration as a metabolic sensor and driver in GBM
For the purposes of this review, the primary functions of RTK pathway signaling are to enable cells to promote anabolic metabolism. One of the master regulators of cancer metabolism is the oncogenic transcription factor, cMyc. 28, 29 c-Myc expression is controlled in a multi-layered way that includes gene rearrangement and amplification, but c-Myc is rarely amplified or mutated in GBM, 2 despite its potential importance in GBM pathogenesis. In GBM, hyperactivated EGFR signaling increases the activity of cMyc through both the phosphoinositide 3-kinase (PI3K)-Akt-mechanistic target of rapamycin complex 1 (mTORC1) pathway, as well as an Akt-independent activity of the mTORC2 complex (Fig. 3) . Mutations in IDH play an important role in gliomas through their neomorphic activity that converts α-KG to an oncometabolite 2-HG. 2-HG, 2-hydroxyglutarate; α-KG, α-ketoglutarate; G-CIMP, glioma with a CpG island methylator phenotype; GSH, reduced glutathione; HIF, hypoxia-inducible factor; IDH, isocitrate dehydrogenase; KDM, histone lysine demethylase; NADPH, reducible form of nicotinamide adenine dinucleotide phosphate; ROS, reactive oxygen species; TCA, tricarboxylic acid; TET, ten-eleven translocation.
IDH1-mutant glioma malignant progression, 32 and RTKand Myc-dependent metabolic reprogramming might be involved in this process. Myc may be further involved in the maintenance of glioma-initiating cells by promoting fatty acid (mevalonate) metabolism, 33 and the role of Myc-dependent metabolism reprogrammed by RTK signaling may be broader in glioma pathogenesis than expected. In addition to reprogramming cellular metabolic circuits, the ability to sense the nutrient status in the microenvironment is necessary for cancer cells to appropriately reprogram intracellular metabolism and ensure cell survival. mTORC1 is an evolutionarily conserved multiprotein complex that functions as a key mediator of protein translation, gene transcription and autophagy. 34 mTORC1 could respond to a range of amino acids and relevant metabolites, including leucine and arginine (Fig. 3) , the mechanism of which could be exploitable for novel therapeutic strategies. 35 In contrast, in human GBM, mTORC2 is activated in glucose-rich conditions by acetylation of Rictor, the main component of mTORC2. 36 This is metabolically mediated by the increased production of acetyl-co-enzyme A (acetyl-CoA), a well-known donor of the acetyl group to the protein. The findings suggest a novel role of mTORC2 as a glucose sensor in cancer cells (Fig. 3) . Furthermore, we recently showed that mTORC2 could suppress the activity of the cystineglutamate antiporter, system Xc transporter-related protein (xCT), 37 implicating new roles for mTORC2 as a potential amino acid sensor (Fig. 3) . These recent studies prompt an unexpected hypothesis for cancer metabolism regarding the sensing mechanism of glucose and amino acid by mTORC2. mTORC2 requires either glucose or acetate for its activated status, 36 and this mTORC2-dependent glucose sensing mechanism would raise the possibility that under nutrient-poor conditions, lower mTORC2 signaling could prefer glutamate efflux, cystine uptake, and glutathione synthesis to protect tumor cells from cellular stress at the expense of cell proliferation, the mechanism of which is based on the mTORC2-dependent regulation of xCT systems (Fig. 3) . 34, 37 The findings lead to the proposal that glucose and amino acid metabolism could interact through mTORC2 signaling, which enables cancer cells to promote their survival according to the microenvironment nutrient status. 38 
METABOLISM-DRIVEN EPIGENETIC SHIFT IN GLIOMAS IDH-dependent modulation of the epigenetic landscape in gliomas
Cancer metabolic reprogramming has been shown to be a consequence of upstream mutations in IDH in LGGs or the RTK signaling networks in IDH wild-type GBM. 39 Recent reports demonstrated that metabolic reprogramming eventually contributing to tumorigenesis. Further, mutant IDH establishes a CD24+ population with a proliferative advantage and stem-like transcriptional features, and prolonged exposure to mutant IDH1 results in irreversible genomic and epigenetic reprogramming. 46 Of interest, recent reports demonstrated that a subtype of IDH-mutant glioma was associated with DNA demethylation and poor outcome, and the DNA methylation landscape of GBM progression shows extensive heterogeneity in time and space. 45, 47 The finding that G-CIMP high gliomas could transform into G-CIMP low tumors at recurrence nominates DNA methylation as crucial determinants for glioma progression and evolution (Fig. 2) .
EGFR-mTOR pathways regulate histone modifications in gliomas
Epigenetic changes to regulate proper gene expression include DNA methylation, histone modifications and noncoding RNAs. Importantly, many enzymes that play important roles in epigenetic gene regulation utilize intermediary metabolites as co-substrates yielded by cellular metabolic reprogramming, and histone modifications are especially sensitive to changes in the level of intracellular metabolites. 8, 40, 41 Of note in this regard, multiple intermediary metabolites can be regulated by PI3K-Akt-mTOR signaling. 41 Acetylation on the N-terminal lysine tail of histones leads to the neutralization of positively charged lysine with an open chromatin configuration facilitating transcription, using acetyl-CoA as the substrate to modify histone tails. Conversely, deacetylation of histones is associated with condensed chromatin and reduction of transcriptional activity. Histone methylation is also important in defining the epigenetic state of chromatin, as well as the methylation of DNA itself. The methyl-donor Sadenosylmethionine (SAM) is utilized by methyltransferases; thus its metabolism can profoundly affect the DNA and histone methylation status. In EGFRmutant GBMs which do not usually possess mutations in IDH or the H3 histone family 3A (e.g. H3K27M, H3G34V/R) to potentially change the epigenetics (Fig. 4A) , [48] [49] [50] [51] constitutive PI3K activation could engage the epigenetic machinery through several complementary routes. Yang et al. demonstrated that activated EGFR promotes the translocation of the glycolytic enzyme pyruvate kinase isozymes M2 (PKM2) to the nucleus where it phosphorylates the tail of histone 3 at Thr11, dissociating histone deacetylase 3 to promote histone acetylation which regulates transcription of the cancer-promoting genes including c-Myc and cyclin D1 (Fig. 4B) . 52 Epigenetic regulation of c-Myc may be a chief mechanism for its overexpression in GBM. 53 Further, we showed that
EGFRvIII remodels the activated enhancer landscape of GBM (represented by H3K4me1 and H3K27ac), promoting tumorigenesis through a SOX9 and FOXG1-dependent transcriptional regulatory network in GBM (Fig. 4B) . 54 We further demonstrated that EGFR-mTOR pathways are important in the modulation of histone acetylation, as well as methylation, in response to intracellular metabolic reprogramming and microenvironment (Masui K, Ikegami S, Harachi M, Yang H, Onizuka H, Yong WH, Cloughesy TF, Muragaki Y, Kawamata T, Arai N, Komori T, Cavenee WK, Mischel PS, Shibata N. unpublished data) (Fig. 4B) , and further studies are necessary to unravel the mechanisms by which glioma cells survive in the various niches through EGFR-mTORdependent dynamic shifts in their epigenetic landscapes.
MOLECULAR THERAPIES TARGETING MUTATION-DEPENDENT METABOLISM IN GLIOMAS Targeting IDH mutations and metabolism
Clinical studies suggest that IDH1 mutation is an independent, favorable prognostic marker in grades II-IV gliomas. 55, 56 Preclinical work with IDH1 mutant mouse xenograft models has shown that continuous expression of IDH1 mutations is required to maintain growth in glioma cells and that pharmacological inhibition of the mutation results in the suppression of tumor growth as well as the induction of differentiation. 57 This promotes mutant IDHtargeting therapies as a novel strategy against glioma (Fig. 5) , and indeed several inhibitors have entered a clinical trial with phase I dose escalation studies. Considering that IDH mutations result in G-CIMP status to block differentiation, therapeutic agents promoting DNA demethylation and differentiation may be effective in treating IDH-mutant tumors (Fig. 5) . 58 Further, preclinical studies showed that inhibitors of mutant IDH1/2 enzymes delayed growth and promoted differentiation in IDH-mutated glioma cells, indicating that mutant IDH enzymes themselves could be a therapeutic target (Fig. 5) . 58 Of interest, bromodomain-containing protein 4; EGFR, epidermal growth factor receptor; H3K9ac, acetylation of the 9th lysine residue in histone H3; K, lysine residues; mTORC2, mechanistic target of rapamycin complex 2; Me, methyl-group; mTOR, mechanistic target of rapamycin; PKM2, pyruvate kinase isozymes M2; SAM, S-adenosylmethionine. immunotherapy may also be a feasible approach to treating IDH-mutant tumors, as it increased survival versus controls in an intracranial glioma model (Fig. 5) . 59 Additionally, other therapeutic agents may be useful for glioma treatment, depending on the presence of IDH mutations. IDH mutation sensitizes glioma cells to cytotoxic agents such as 5-FU treatment through the reduction of antioxidants (NADPH and GSH) by mutant IDH, and to poly-adenosine diphosphate ribose polymerase inhibition via inducing a mutant IDH-dependent homologous recombination defect (Fig. 5) . 60, 61 From the metabolic viewpoint, mutant IDH1 lowered NAD + levels by downregulating the NAD + salvage pathway enzyme nicotinate phosphoribosyltransferase (NAPRT1), sensitizing to NAD + depletion via concomitant nicotinamide phosphoribosyltransferase (NAMPT) inhibition, identifying NAD + depletion as a metabolic susceptibility of IDH1 mutant cancers (Fig. 5) . 62 Moreover, small-molecule inhibitors against mutant IDH could be the therapeutic strategies to target mitochondrial bioenergetics for cancer cells. 63 The specific nature of IDH mutation in gliomas may be further exploited for 2-HG-targeting diagnostics and biomarkers (Fig. 5) . [64] [65] [66] Further data are required to establish the role of IDH mutation and 2-HG in clinical diagnostics and therapeutics.
G-CIMP
EGFR-targeting therapy and extrachromosomal DNA
The amplification of oncogenes can be found either within chromosomes or as nuclear extrachromosomal DNA (ecDNA) elements, traditionally known as double minutes (DMs) (Fig. 1B) . ecDNAs have been found to have important roles in tumorigenesis including gliomagenesis, and the magnitude and frequency of these somatic alterations and their impact on tumor evolution have been recently unraveled. 67 It has been now demonstrated that resistance to EGFR tyrosine kinase inhibitors (TKIs) in GBM can be mediated by dynamic and reversible hideand-seek of extra-ecDNA (Fig. 6) . 68 We recently showed that nearly all amplified and/or mutated EGFR is present on ecDNA and, in response to EGFR TKI treatment, loss of EGFRvIII from ecDNA renders GBM cells insensitive to TKIs, an unrecognized mechanism to promote drug resistance by cancer cells. Remarkably, the level of EGFRvIII is rapidly restored to drive tumor regrowth upon drug withdrawal. Tumor cells with the re-emerged ecDNA and high levels of EGFRvIII at the end of erlotinib (EGFR TKI) treatment eventually repopulate the tumor mass. Of note, through integrated genomic, cytogenetic, and bioinformatics analyses, we also demonstrated that ecDNA was found in nearly half of human cancers, but it was almost never found in normal cells. 69 Driver oncogenes were amplified most commonly in ecDNA, and ecDNA amplification would be predicted to increase oncogene copy number and intratumoral heterogeneity more effectively than chromosomal amplification, suggesting that ecDNA contributes to accelerated evolution in cancer. 67, 69 These surprising findings challenge our understanding of the "Map" of cancer genome abnormalities and suggest that not only oncogene copy number, but also the sub-nuclear localization of oncogene DNA, may potentially contribute to tumor development and progression, as well as drug resistance.
70
Targeting mTOR-dependent metabolism mTOR complexes play a critical role in regulating signal transduction which is critical to developing more effective therapies to target metabolic reprogramming in gliomas. 34 This sheds light on the resistance mechanisms of GBM to molecularly targeted therapies, providing compelling rationale for the combined inhibition of PI3K/Akt and mTORC2 as a promising "combinatorial targeted therapy" for targeting c-Myc and cancer metabolism (Fig. 6 ).
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In contrast, the convergence of multiple upstream signaling pathways on c-Myc raises the possibility that bromodomain and extraterminal (BET) bromodomain inhibitors, that interfere with BET family protein binding to lysine-acetylated histone tails to suppress c-Mycdependent target gene expression, may have a role in solid tumors with mTOR activation, including GBM. 72 mTOR is essential in integrating various metabolic circuits with signal transduction. mTORC1 was reported to be a critical effector downstream of the tumor suppressor liver kinase B1 through adenosine monophosphate-activated protein kinase (AMPK). We demonstrated that the AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) influences the growth of EGFR-activated GBM through the inhibition of lipogenesis (Fig. 6 ). 73 We also showed that EGFR signaling activates the transcriptional regulator of fatty acid synthesis, sterol regulatory elementbinding protein-1 (SREBP-1), 74 leading to SREBP-1-dependent tumor survival through the regulation of lowdensity lipoprotein receptor (LDLR). 75 Of interest, targeting LDLR with a liver X receptor (LXR) agonist caused LDLR degradation, potently promoting GBM cell death in an animal model (Fig. 6 ). Possibly through these mechanisms, GBM is remarkably dependent on cholesterol for survival and sensitive to LXR agonist-dependent cell death, based on the tumor's co-dependencies shaped both by aberrant EGFR-mTOR signaling and the brain's unique biochemical environment. 76 Additionally, combination of an xCT inhibitor, erastin, with Torin1 (dual mTOR kinase inhibitor) resulted in significant synergistic GBM cell death, indicating that increased xCT activity has a major contribution to glutathione synthesis and GBM cell survival upon pharmacological mTOR kinase inhibition (Fig. 6 ). 37 Furthermore, nuclear factor-κB-mediated survival through mutant EGFR-mTOR signaling could contribute to a novel resistance mechanism of GBM cells to chemotherapy as well as TKI treatment. 77, 78 Thus, understanding the regulation of cellular metabolism with mTOR signaling may pave the way for developing more effective treatment strategies and point out the necessity to consider the complementary approach to combine the cytotoxic and molecular-targeting therapies in a rational manner. 79 
CONCLUSION AND FUTURE PERSPECTIVE
Cancer is a disease of endogenous somatic mutations, and the traditional phenotypic classifications of diffuse gliomas have been replaced by those based on recent identification of distinct genetic and epigenetic profiles in each glioma entity. The association between genetic aberrations and glioma pathogenesis, including epigenetic changes and therapeutic resistance, is through reprogramming of the metabolic pathways. Cancer metabolism in IDH-mutated
LGGs is potentially linked to the global change in the epigenetic landscape, including the shift in the genome-wide methylome through the action of oncometabolites. Metabolism in IDH-wild-type GBM is mainly reprogrammed by hypoxia and RTK-dependent c-Myc activation to modulate the cellular metabolome as well as histone modifications, causing resistance to cancer therapeutics. Tumor development, progression and therapy response are profoundly influenced by tumor cells' intracellular metabolism and the exogenous microenvironment. The biochemical environment can shape the behavior of tumor cells in a genotype-specific fashion. Further, the heterogeneity in tumor metabolism and epigenetic changes should be taken into consideration. 80 Interestingly, aggressiveness and recurrence seem to be parallel with the status of epigenetic heterogeneity in a time-and space-dependent manner. Additionally, the idea of specifically targeting the formation of episomal events should be incorporated into the treatment strategies as well as with rational combination of cytotoxic and molecular targeted therapies, in order to effectively target the metabolic and epigenetic networks on which glioma cells heavily depend. Future studies are needed to determine precisely how the main genetic mutations specific for each glioma entity facilitate cancer metabolic reprogramming and epigenetic shifts and how at the same time extracellular nutrients modulate oncogenic signaling in order to translate these insights into more effective treatments for glioma patients.
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